- Home
- SHOT vs LSTA Comparison
SHOT vs LSTA Comparison
Compare SHOT & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHOT
- LSTA
- Stock Information
- Founded
- SHOT 2018
- LSTA 1980
- Country
- SHOT United States
- LSTA United States
- Employees
- SHOT N/A
- LSTA N/A
- Industry
- SHOT Biotechnology: Pharmaceutical Preparations
- LSTA Misc Health and Biotechnology Services
- Sector
- SHOT Health Care
- LSTA Health Care
- Exchange
- SHOT Nasdaq
- LSTA Nasdaq
- Market Cap
- SHOT 83.7M
- LSTA 22.3M
- IPO Year
- SHOT 2020
- LSTA N/A
- Fundamental
- Price
- SHOT $0.30
- LSTA $2.33
- Analyst Decision
- SHOT
- LSTA Strong Buy
- Analyst Count
- SHOT 0
- LSTA 2
- Target Price
- SHOT N/A
- LSTA $23.50
- AVG Volume (30 Days)
- SHOT 3.6M
- LSTA 21.8K
- Earning Date
- SHOT 11-13-2025
- LSTA 11-11-2025
- Dividend Yield
- SHOT N/A
- LSTA N/A
- EPS Growth
- SHOT N/A
- LSTA N/A
- EPS
- SHOT N/A
- LSTA N/A
- Revenue
- SHOT N/A
- LSTA $1,070,000.00
- Revenue This Year
- SHOT N/A
- LSTA N/A
- Revenue Next Year
- SHOT N/A
- LSTA N/A
- P/E Ratio
- SHOT N/A
- LSTA N/A
- Revenue Growth
- SHOT 246.36
- LSTA N/A
- 52 Week Low
- SHOT $0.23
- LSTA $1.87
- 52 Week High
- SHOT $1.77
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- SHOT 33.94
- LSTA 48.64
- Support Level
- SHOT $0.30
- LSTA $2.10
- Resistance Level
- SHOT $0.45
- LSTA $2.33
- Average True Range (ATR)
- SHOT 0.03
- LSTA 0.17
- MACD
- SHOT -0.00
- LSTA 0.01
- Stochastic Oscillator
- SHOT 2.75
- LSTA 54.17
About SHOT Safety Shot Inc.
Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.